US › Healthcare

AIM ImmunoTech Inc (AIM)

US · Healthcare · Biotechnology

$0.15+1.91%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$26,000

Revenue YoY

+4.0%

Net profit

$-3.8M

EPS

$-0.43

EPS estimate

$-0.12

Net margin

-14,569.2%

EPS came in at -0.43 against a street estimate of -0.12 — a miss of 258.3%.

Key statistics

Market cap

$6.1M

Forward P/E

2.0

P/B

0.83

Book value

$0.27

EPS (TTM)

$-2.81

52-week high

$1.75

52-week low

$0.15

50-day MA

$0.19

200-day MA

$0.47

Beta

1.31

Analyst view

Analysts rate AIM ImmunoTech Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $4.25.

Shareholding

Insiders

0.67%

Institutions

2.97%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AIM ImmunoTech Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.